Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT) company Zetiq Technologies Ltd. has launched a study to assess the feasibility of its bladder cancer identification and diagnosis technology.
The company has begun the first of two areas of study the identification and diagnosis of bladder cancer. The second research goal is to assess the technology's efficacy as a survey technology to locate and provide early warning to potential victims of the disease, as well as a way to follow the course of the disease after treatment.
Zetiq expects preliminary results in the second half of 2009.
Zetiq has developed techniques for differential marking of specific cell populations at very early stages. Normal and malignant cells stain differently when exposed to the company’s system. This enables fast and precise detection of rare cell types within a larger population of cells and distinguishes between normal and malignant cells.
Last week, Zetiq reported that a study proved that its cervical cancer diagnostic test was as reliable as the current benchmark test for the disease.
Shares in Bio-Light are up over 11% on the TASE, after trading lower in the morning. As of yesterday's closing price, Bio-Light shares were up 296% for the year.
Published by Globes [online], Israel business news - www.globes-online.com - on January 15, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009